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Background: A set of standard clinical chemistry and hematology parameters are usually measured during clinical
studies. The major outcome of these standard tests is to control that the drug investigated does not lead to
pathophysiological changes in respective organs or blood. In some cases based on scientific rationale such tests
may not be needed.
In this paper we report on a standard set of clinical chemistry and hematology laboratory parameters measured
before and after treatment in three different immunotherapy studies, representing different routes of administration
and different formulations.
Methods: Thirteen hematological laboratory parameters and eight clinical chemistry parameters were evaluated
from three double-blind, placebo-controlled, randomized, multi-centre, phase III studies. The three studies include
one with sublingual immunotherapy (n = 185), one subcutaneous immunotherapy trial with an aluminium
hydroxide-adsorbed recombinant hypoallergenic Bet v1-FV (n = 211) and one with pre-seasonal subcutaneous
immunotherapy with a 6-grass pollen allergoid (n = 154).
Results: Allergen specific immunotherapy with both administration forms and formulations respectively did not
show any influence on any of the 21 laboratory parameters analyzed. Few patients had a change in laboratory
parameters from within normal range at baseline to either below or above at end-of-treatment. No differences
between active and placebo were seen with respect to number of patients with such a change.
Conclusions: This study with different preparations and routes of application indicates that the value of repeated
measurements of standard clinical chemistry and hematology parameters during allergen immunotherapy should
be discussed further.
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As a routine analysis for evaluation of safety in clinical
development programs for new drugs, a set of standard
clinical chemistry and hematology parameters are mea-
sured. The major outcome of these standard tests is
to control that the drug investigated does not lead
to pathophysiological changes in respective organs or
blood. Guidelines from EMA on safety pharmacology
studies discuss such a pharmacology core battery for* Correspondence: dietrich.haefner@allergopharma.de
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unless otherwise stated.investigation of vital functions and that in some cases
based on scientific rationale such tests may not be
needed [1]. In the present paper we focus on clinical
chemistry and hematology variables, only.
Allergen specific immunotherapy is known to be an
efficient treatment for respiratory allergic diseases and
based on clinical investigations also shown to have a
good safety profile including only potential allergic side
effects in patients already allergic to the allergen they
are treated with [2]. In recent years new administration
forms and formulations of allergens are being devel-
oped [3] and many studies are ongoing and being
planned. The recent guidelines from EMA on clinicalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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immunotherapy discuss safety parameters which should
be addressed such as routine laboratory hematology,
biochemical tests and urinalysis [4].
In this paper we report on a standard set of clinical
chemistry and hematology laboratory tests measured be-
fore and after treatment in three different immunotherapy
studies, representing different routes of administration
and different formulations.
Methods
Thirteen hematological laboratory parameters and eight
clinical chemistry parameters (Table 1) were evaluated
from three double-blind, placebo-controlled, randomized,
multi-centre, phase III studies. Median values of each la-
boratory parameters from baseline and after treatment
(end of the double-blind treatment period) were com-
pared. The three studies included a total of 550 adult
patients (271 on placebo and 279 on active treatment)Table 1 Hematology and blood chemistry laboratory
parameters measured in the three phase III clinical
studies
























1N/A on Pre-seasonal SCIT 6-grass.
2N/A on SCIT rBirch.
Normal ranges modified from Kratz et al. [5].suffering from either birch or grass pollen allergic rhino-
conjunctivitis with or without asthma.
The first study was performed with sublingual immuno-
therapy (SLIT) of the high dose grass pollen preparation
(ALLERSLIT® forte) (SLIT 6-grass study) and included
185 patients [6,7]. Mean age of patients was 33.2 years
(SD 10.3, range 17–59); 63% of patients were male, 37%
female. The second trial evaluated subcutaneous immuno-
therapy (SCIT) with an aluminium hydroxide-adsorbed
recombinant hypoallergenic variant of the major birch
pollen allergen (rBet v1-FV) (SCIT rBirch study) and in-
cluded 211 patients [8]. Mean age of patients was
38.2 years (SD 11.0, range 18–59); 47% of patients were
male, 53% female. The third study assessed pre-seasonal
SCIT of grass pollen allergoid (Allergovit®) (pre-seasonal
SCIT 6-grass study) and included 154 patients [9]. Mean
age of patients was 34.4 years (SD 10.6, range 18–60); 42%
of patients were male, 58% female.
All patients had a history of IgE-mediated seasonal al-
lergic rhinitis/conjunctivitis with or without asthma
(GINA stage I and II) caused by grass pollen (grass stud-
ies) or birch pollen (birch study), positive skin prick test
result to grass pollen extract (grass studies) or birch
pollen extract (birch study), and positive conjunctival
provocation test with grass pollen allergens (grass stud-
ies) or birch pollen allergens (birch study). Only patients
with moderate to severe allergic symptoms to grass or
birch pollen were included in the clinical trials. Patients
were excluded if they previously had undergone grass or
birch pollen immunotherapy or suffered from other sea-
sonal allergies in the same period as the relevant grass
or birch pollen, or had a history of cardiovascular or
other immunological or medically relevant diseases.
After up-dosing patients in the SLIT 6-grass study were
treated daily with high-dose sublingual 6-grass pollen
preparation (Holcus lanatus, Dactylis glomerata, Lolium
perenne, Phleum pratense, Poa pratensis, and Festuca ela-
tior) or placebo from January 2004 until end of grass
pollen season in 2005. The group 5 allergen content of the
active maintenance dose corresponded to 40 μg. Patients
in the SCIT rBirch study were treated with subcutaneous
injections of recombinant hypoallergenic variant of the
major birch pollen allergen (rBet v1-FV, maintenance dose
80 μg every 6 ± 2 weeks) or placebo from October 2004
until end of birch pollen season in 2006. Treatment of
patients in the SCIT 6-grass study included pre-seasonal
weekly injections with either 6-grass pollen (Holcus
lanatus, Dactylis glomerata, Lolium perenne, Phleum
pratense, Poa pratensis, Festuca pratensis) allergoid or
placebo until the expected onset of the grass pollen sea-
son 2001 and 2002.
Written informed consent was obtained from the pa-
tients before they were enrolled in the studies, and the
studies were performed in accordance with good clinical
Table 2 Baseline values for measured hematology and blood chemistry parameters (SLIT 6-grass: n = 91 for placebo and n = 94 for active treatment; SCIT rBet
v1-FV: n = 103 for placebo and n = 108 for active treatment; pre-seasonal SCIT 6-grass: n = 77 for placebo and n = 77 for active treatment)
SLIT 6-grass SCIT rBirch Pre-seasonal SCIT 6-grass
Parameter (unit) Placebo Active Placebo Active Placebo Active
Hematology Median Range Median Range Median Range Median Range Median Range Median Range
Platelets [1000/μL] 247.5 [134.0; 401.0] 249 [148.0; 393.0] 247 [149.0; 429.0] 236 [121.0; 369.0] 249 [100.0; 462.0] 261 [152.0; 377.0]
Leukocytes [1000/μL] 6.4 [3.2; 12.5] 6.3 [3.1; 14.6] 6 [3.3; 12.8] 5.8 [3.1; 12.1] 6.5 [3.7; 11.8] 6 [3.6; 14.6]
Lymphocytes [%] 26.3 [16.5; 42.7] 27 [14.6; 47.0] 31.4 [1.7; 61.0] 33.8 [8.8; 63.0] 29 [2.5; 52.7] 31.2 [2.7; 49.1]
Basophils [%] 0.6 [0.0; 1.9] 0.6 [0.0; 1.8] 0.6 [0.0; 2.1] 0.6 [0.0; 3.7] 0.5 [0.0; 1.8] 0.7 [0.0; 3.9]
Eosinophils [%] 1.9 [0.7; 16.1] 2 [0.0; 10.5] 2.4 [0.0; 11.1] 2.7 [0.7; 8.4] 2.3 [0.3; 10.3] 2.7 [0.1; 10.7]
Monocytes [%] 6.6 [0.3; 11.2] 6.2 [3.3; 12.2] 6.6 [2.6; 13.3] 7 [2.8; 17.0] 6.9 [0.5; 16.9] 6.9 [0.9; 15.7]
Neutrophils [%] 60 [1.0; 76.2] 60 [43.0; 77.4] 58 [30.0; 92.3] 55.7 [25.0; 86.0] 58.8 [34.0; 86.8] 56.6 [38.6; 72.8]
Erythrocytes [106/μL] 4.8 [3.8; 6.0] 4.8 [4.0; 6.0] 4.8 [3.8; 5.8] 4.7 [3.6; 5.5] 4.62 [3.8; 5.8] 4.65 [3.9; 5.9]
Haematocrit [%] 44 [36.9; 52.0] 44.1 [34.0; 55.2] 42 [35.0; 51.0] 41.9 [33.0; 56.0] 42 [32; 50.0] 41.1 [26.9; 52.2]
Haemoglobin [g/dL] 14.7 [12.0; 18.0] 14.9 [12.0; 18.3] 14.4 [11.6; 16.8] 14 [10.5; 17.2] 14.1 [9.9; 17.4] 14.01 [8.0; 17.3]
MCH [pg] 29.5 [21.0; 33.1] 29.7 [21.0; 90.0] 30 [25.0; 33.8] 30.3 [23.0; 34.0] ND ND ND ND
MCHC [g/dL] 32.9 [30.3; 35.5] 33.3 [29.9; 36.5] 34 [29.1; 36.2] 33.6 [27.3; 36.9] ND ND ND ND
MCV [fL] 88.8 [83.0; 103.0] 89 [76.0; 106.0] 89 [76.0; 105.0] 90 [72.0; 108.0] ND ND ND ND
Blood chemistry
Potassium [mmol/L] 4.2 [3.1; 5.4] 4.2 [3.7; 7.3] 4.2 [3.3; 6.2] 4.2 [3.1; 7.3] 4.8 [3.5; 10.0] 4.6 [3.7; 10.0]
Sodium [mmol/L] 140 [134.0; 148.4] 140 [134.0; 149.5] 140 [133.0; 147.0] 140 [127.0; 146.4] 139 [132.0; 139.0] 139.1 [133.0; 147.0]
Gamma-GT [U/L] 16 [7.0; 72.0] 19 [4.0; 243.0] ND ND ND ND 14 [5.0; 58.0] 19 [4.0; 190.2]
SGOT (AST) [U/L] 21 [6.0; 42.0] 23.5 [8.0; 62.0] 23 [8.0; 51.0] 25 [11.0; 72.0] 14.5 [5.0; 31.0] 15 [5.0; 36.0]
SGPT (ALT) [U/L] 20 [6.0; 56.0] 24 [7.0; 93.0] 22 [5.4; 84.0] 22 [6.0; 113.0] 18 [4.0; 18.0] 18.6 [5.0; 61.0]
Creatinine [mg/dL] 0.9 [0.5; 1.4] 0.9 [0.6; 1.3] 0.9 [0.5; 1.3] 0.8 [0.3; 1.3] 0.9 [0.6; 1.3] 0.9 [0.6; 1.4]
Bilirubin [mg/dL] 0.7 [0.2; 1.5] 0.7 [0.2; 3.1] 0.6 [0.1; 2.8] 0.5 [0.2; 2.5] 0.6 [0.2; 2.1] 0.6 [0.2; 2.7]
Urea [mg/dL] 29 [17.0; 53.0] 29 [19.0; 54.0] 28 [10.0; 47.0] 27 [10.0; 47.0] 26 [12.0; 52.0] 26 [6.4; 43.2]
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tries approved the studies. A list of all participating ethics
committees is included in Additional file 1. Matching
placebo solutions were used as comparator in all three
studies. All study preparations were manufactured by
Allergopharma GmbH & Co. KG, Reinbek, Germany.
Results
Demographic and baseline characteristics showed that
the two treatment groups in all three studies were well
matched in terms of baseline characteristics. Details of
efficacy and safety outcome as well as specific immuno-
logical measures are described elsewhere [6,8,9].
No differences were observed between placebo and ac-
tive groups at baseline regarding hematology and clinical
chemistry parameters. The baseline median values for all
three studies are shown in Table 2.Figure 1 Absolute change from baseline to end of treatment for hem
parameters (SLIT 6-grass: n = 91 for placebo and n = 94 for active treaAllergen specific immunotherapy with either adminis-
tration form or formulation did not show any influence
on any of the 21 laboratory parameters analyzed (Figures 1,
2 and 3). The changes in median values were insignificant
and there were no differences between placebo patients
and actively treated patients in any of the studies.
Few patients had a change in laboratory parameters
from within normal range at baseline to either below or
above at end-of-treatment. No differences between ac-
tive and placebo were seen with respect to number of
patients with such a change. The numbers of analyses in
the respective treatment groups which have changed to
values outside the defined normal range are listed in
Table 3. The laboratory parameters where most analyses
showed a change were leukocytes, neutrophils, eosino-
phils, lymphocytes and monocytes; however no differ-
ences between active and placebo were observed.atology (upper panel) and blood chemistry (lower panel)
tment).
Figure 2 Absolute change from baseline to end of treatment for hematology (upper panel) and blood chemistry (lower panel)
parameters (SCIT rBet v1-FV: n = 103 for placebo and n = 108 for active treatment).
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We selected thirteen hematology laboratory parameters
and eight clinical chemistry parameters as a standard test
battery in order to control that the different allergen for-
mulations and routes of administration did not lead to
pathophysiological changes in respective organs or blood.
We performed the tests prior to treatment and found
that among patients selected for immunotherapy, the
pathophysiology and the patient’s allergic disease history
had not lead to abnormal values. Only a few analysis re-
sults were outliers in relation to the defined normal range
of distribution in the standard population. Since the most
important contraindication for allergen specific immuno-
therapy are cardiovascular and immunological diseases
[10] it seems relevant to measure standard tests whichcould indicate other important disorders than allergy in
the individual patient initially recruited. Other laboratory
tests of specific interest in relation to allergen specific im-
munotherapy are measures of specific antibodies such as
IgE and IgG4 [11]. These antibodies are directly related to
the pathophysiology of respiratory allergic diseases and
the immunological changes in these antibodies following
treatment is related to the clinical effects [12,13]. These
antibodies should usually be measured during investiga-
tions of allergen specific immunotherapy.
We selected three different immunotherapy studies, all
performed in adults with the purpose of following the
basic laboratory parameters during treatment. In all these
studies we found an increase in the induction of specific
antibodies [6,9,14] but allergen specific immunotherapy
Figure 3 Absolute change from baseline to end of treatment for hematology (upper panel) and blood chemistry (lower panel)
parameters (Pre-seasonal SCIT 6-grass: n = 77 for placebo and n = 77 for active treatment).
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in the basic clinical chemistry and hematology parameters.
The three studies represented three different approaches
for allergen specific immunotherapy. In principle the in-
clusion criteria were the same in all three studies and the
treatment period was up to 24 months. One study was
performed with a standard pre-seasonal grass pollen aller-
gen extract given as weekly injections for two consecutive
pre-seasonal periods and another study performed with
sublingual treatment including daily self-administration
for two years. The last study included was performed
with a recombinant major allergen vaccine for birch al-
lergy (rBet v1-FV). Independently of administration route
and formulation we found no significant changes in
basic blood chemistry or hematology measures during the
study period. We conclude that the allergen specificimmunotherapy treatment as investigated did not lead to
abnormal changes in basic immunological and metabolic
processes. This is in accordance with an earlier publication
[15]. Since the active drugs in this case are natural occur-
ring protein substances or well defined recombinant pro-
teins there are also no scientific rationale for expecting
major changes in the parameters we investigated except
the induction of specific antibodies.
Conclusion
The Guidelines from EMA on safety pharmacology stud-
ies conclude that the basic pharmacology core battery
for investigation of vital functions based on scientific ra-
tionale can in some situations be saved [1]. With this
paper we confirm such a scientific rationale and con-
clude that the evaluation of these parameters is relevant
Table 3 Number of patients with a change in hematology
and blood chemistry parameter from normal at baseline
to below or above the defined normal range at end of
treatment
Parameter (Unit) Placebo (n = 271) Active (n = 279)
Hematology
Platelets [1000/μL] 5 2
Leukocytes [1000/μL] 15 21
Lymphocytes [%] 32 26
Basophils [%] 8 13
Eosinophils [%] 26 33
Monocytes [%] 17 16
Neutrophils [%] 25 27
Erythrocytes [106/μL] 17 13
Haematocrit [%] 17 13
Haemoglobin [g/dL] 15 13
MCH [pg]1 11 9
MCHC [g/dL]1 15 15
MCV [fL]1 9 9
Blood chemistry
Potassium [mmol/L] 11 13
Sodium [mmol/L] 9 7
Gamma-GT [U/L]2 6 3
SGOT (AST) [U/L] 3 5
SGPT (ALT) [U/L] 10 8
Creatinine [mg/dL] 12 9
Bilirubin [mg/dL] 3 4
Urea [mg/dL] 4 7
1N/A on Pre-seasonal SCIT 6-grass.
2N/A on SCIT rBirch.
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This study with different preparations and routes of ap-
plication indicates that the value of repeated measure-
ments of standard clinical chemistry and hematology
parameters during allergen immunotherapy should be
discussed further.Additional file
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